Handelsbanken Fonder AB Sells 1,900 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Handelsbanken Fonder AB decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 14.6% in the 4th quarter, Holdings Channel reports. The firm owned 11,100 shares of the biotechnology company’s stock after selling 1,900 shares during the quarter. Handelsbanken Fonder AB’s holdings in United Therapeutics were worth $3,917,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after purchasing an additional 45,566 shares during the period. FMR LLC lifted its position in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the period. Pacer Advisors Inc. lifted its position in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after purchasing an additional 30,931 shares during the period. Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 12.3% in the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after purchasing an additional 50,409 shares during the period. Finally, Assetmark Inc. lifted its position in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,164 shares of company stock worth $41,671,293. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Down 1.7 %

Shares of UTHR stock opened at $361.10 on Monday. The firm has a market capitalization of $16.12 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The firm has a fifty day simple moving average of $362.68 and a two-hundred day simple moving average of $360.72. United Therapeutics Co. has a 12 month low of $214.75 and a 12 month high of $417.82.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.